However, due to the fluctuating levels of BCMA expression in malignant plasma cells, BCMA downregulation, and the heterogeneous nature of tumor antigens in MM, researchers are investigating additional target antigens, including CD19, SLAMF7, GPRC5D, CD138, CD38, CD70, NKG2DL, and kappa/lambda light chains [10]. The gene discussed is TNFRSF17; the disease is neoplasm.